This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Biotech Stock Mailbag: Celldex, Hep C Bubble, Al Mann Anger

Gee, they were only off by six gazillion percent.

And check this out: Back in January 1998, Morgan Stanley Dean Witter analyst Paul Brooke, covering Pfizer, wrote a research note in which he forecast 2004 Lipitor sales of $7.4 billion. Actual 2004 Lipitor sales: $10.9 billion! (Huge thanks to Saira Ramasastry of Life Sciences Advisory for sending me this fascinating relic of sell-side history.)






I took a somewhat dim view of the clinical benefit for colon cancer patients derived from the Bayer-Onyx Pharmaceuticals (ONXX) drug regorafenib. Reader Steve W. thinks I'm missing the point:

"On your article regarding regorafenib, a few things you didn't mention that you probably should have to place regorafenib in proper perspective. The six weeks is the median survival, with half of patients doing better and half doing worse, an important point with the investigators already saying the responses were variable, with some patients exceeding survival expectations by more than a year. You also describe three side effects as 'severe,' but when compared to the side effects caused by other approved drugs for colon cancer, they are very similar to those side effects and actually occur in a relatively small percentage of patients. This kind of context is important, and when left out results in your readers getting an inflated sense of risks and a minimized sense of the benefit of this new drug. With nothing new coming out for colon cancer for quite a few years, this is an important advance and FDA should be hurrying to approve it."






Finally, Robin is ticked off about the photo I posted to Twitter last week showing Mannkind (MNKD) CEO Al Mann presenting to an almost-empty room.

"Regarding your stupid Twitter photo on Al Mann at healthcare conference today: 1) there were at least twelve hot shots in the room. You didn't bother to find out who they were, I did. 2) Most people were already needing to leave the conference early; not Al's fault. 3) An 8 am timetable is probably not beneficial to Al Mann after people have been up at fancy dinners and drinking all night the evening before. Most people don't make it to an 8 am conference (hangovers are common). 4) There is something really, really mentally ill (sadistic) about a person who is obsessed with Al Mann, bashing him constantly. If you hate the stock that much, it's already depressed in the price per share, then quit reporting your shabby homework on it. You look unprofessional, worse, you look stupid and ill informed. I think you are paid to SHORT, kind of like a prostitute who has to grovel for cash every day. You just can't make it on your own, like the rest of us professional investors. Why does TheStreet employ a guy who can't do decent homework? YOU ARE A GOOD LAUGH. SEE YA AT APPROVAL WITH MNKD!!!"

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Follow TheStreet on Twitter and become a fan on Facebook.

Stock quotes in this article: CLDX, AVNR, IDIX, ACHN, GILD, MNKD, ONXX 
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.9670 -34.4910 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs